bioAffinity advances CyPath Lung test for lung cancer survivor surveillance
bioAffinity Technologies said it is advancing the potential application of its CyPath Lung test for surveillance of lung cancer survivors.
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it is advancing the potential application of its CyPath® Lung test for surveillance of lung cancer p…